{"id":"W2158082603","doi":"10.2147/ijnrd.s48496","title":"Optimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidence","year":2014,"lang":"en","type":"review","venue":"International Journal of Nephrology and Renovascular Disease","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre; Université de Montréal","funders":"","keywords":"Pazopanib; Axitinib; Temsirolimus; Sunitinib; Everolimus; Medicine; Oncology; Renal cell carcinoma; Internal medicine; Bevacizumab; Sorafenib; Intensive care medicine; Discovery and development of mTOR inhibitors; PI3K/AKT/mTOR pathway; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005046606,0.0005291376,0.001827093,0.0004963716,0.00008829646,0.00004459209,0.0002681581,0.0001540843,0.00008579588],"category_scores_gemma":[0.0001829105,0.0003529596,0.001204949,0.00008270861,0.0002009497,0.000134728,0.0001261781,0.0004278126,0.000006764358],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002105996,"about_ca_system_score_gemma":0.0005737488,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000004884026,"about_ca_topic_score_gemma":0.000003624207,"domain_scores_codex":[0.9973855,0.0002138052,0.001107925,0.0004898881,0.0005188265,0.0002840381],"domain_scores_gemma":[0.9971255,0.0005077255,0.0009563801,0.0002986498,0.0005465507,0.0005651858],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.004756244,0.002047435,0.0005794902,0.02412787,0.01384724,0.004966296,0.0001176212,0.00008674244,0.0000196625,0.00006779699,0.001642785,0.9477408],"study_design_scores_gemma":[0.008496751,0.003058384,0.002439152,0.009090849,0.03619975,0.005156283,0.000005880789,0.0002096367,0.00002357396,0.0001870999,0.9347045,0.0004281111],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.03241604,0.9643196,0.001226145,0.0004367711,0.0004953308,0.0009410398,0.0001500415,0.000007588381,0.000007414174],"genre_scores_gemma":[0.01550757,0.9815425,0.001231593,0.0001818293,0.0009456691,0.00009218101,0.0002469704,0.00005170795,0.0001999814],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9473127,"threshold_uncertainty_score":0.9998922,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0656559042160513,"score_gpt":0.3575867527509122,"score_spread":0.2919308485348608,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}